Abstract
Patients suffering from autoimmune hepatitis, a chronic immune-mediated liver disease with an incidence of 0.9 to 2 per 100,000 population per year in Europe, are considered to have a particularly increased risk for coronavirus disease 2019 (Covid-19)-associated hospitalization and death. 1,2 Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) vaccination provides an essential tool to reduce morbidity and mortality in this cohort. However, a large multicenter study in China has shown a lower immunogenic response to inactivated whole-virion SARS-CoV-2 vaccines of chronic liver disease patients in comparison with the healthy population. 3 Furthermore, reports from inflammatory bowel diseases or rheumatic disorders showed a reduced serologic response in patients taking glucocorticoids or thiopurine. 4,5 The decrease in vaccine-induced antibodies over time, as well as the emergence of variants of concern, led to the recommendation of an additional vaccination in immunocompromised patients.
【초록키워드】 coronavirus disease, SARS-CoV-2, coronavirus, Europe, vaccination, Hospitalization, variants of concern, Immunocompromised patients, glucocorticoid, Inflammatory bowel disease, China, Cohort, Patient, death, morbidity and mortality, incidence, multicenter, inactivated, Serologic response, Immune-mediated, chronic liver disease, Liver disease, Autoimmune hepatitis, acute respiratory syndrome, increased risk, immunogenic, disorder, decrease, shown, reduced, provide, reduce, the healthy, vaccine-induced antibody, whole-virion SARS-CoV-2 vaccine, 【제목키워드】 SARS-CoV-2, response,